The SLC39A1-DRP1 axis: A paradigm shift in targeting mitochondrial dynamics for HCC therapy

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.

[2] Cha DI, Kim JM, Jeong WK, et al. Recurrence-free survival after liver transplantation versus surgical resection for hepatocellular carcinoma: role of High-risk MRI features. Transplantation. 2023.

[3] Li R, Wang Z, Cheng L, et al. Coordination of SLC39A1 and DRP1 facilitates HCC recurrence by impairing mitochondrial quality control. Clin Transl Med. 2025; 15(5):e70362.

[4] Bao D, Zhao J, Zhou X, et al. Mitochondrial fission-induced mtDNA stress promotes tumor-associated macrophage infiltration and HCC progression. Oncogene. 2019; 38(25): 5007-5020.

[5] Ma X, Zhuang H, Wang Q, et al. SLC39A1 Overexpression is associated with immune infiltration in hepatocellular carcinoma and promotes its malignant progression. J Hepatocell Carcinoma. 2022; 9: 83-98.

[6] Zhang H, Zhang Y, Zhu X, et al. DEAD Box Protein 5 Inhibits Liver Tumorigenesis by Stimulating Autophagy via Interaction with p62/SQSTM1. Hepatology. 2019; 69(3): 1046-1063.

[7] Golovine K, Makhov P, Uzzo RG, Shaw T, Kunkle D, Kolenko VM. Overexpression of the zinc uptake transporter hZIP1 inhibits nuclear factor-kappaB and reduces the malignant potential of prostate cancer cells in vitro and in vivo. Clin Cancer Res. 2008; 14(17): 5376-5384.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.